Nermin Tepe

Dr. Nermin Tepe

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
NTNermin Tepe
Nermin Tepe
OTOktay Faysal Tertemi̇z
Oktay Faysal Tertemi̇z
Background /aim: In this study we aimed to compare the efficacy of greater occipital nerve (GON) block alone and GON combined with supraorbital nerve (SON) block was evaluated in the treatment of medication overuse headache (MOH) . 82 patients were divided into two groups; 41 patients were administered bilateral GON block and the other 41 patients GON + SON block. Nerve blocks were administered every 10 day for total 5 sessions. After each administration and 20 days after the last injection, pre and post treatment numerical rating scale (NRS) score, number of painful days, analgesic intake, duration of pain were collected. The decrease in headache evaluation parameters was similar in both groups after the block. The NRS scores in the GON and GON + SON groups before the treatment was 8.2 ± 0.7, 8.5 ± 0.7, the number of painful days in a month was 21.4 ± 6.9, 21.2 ± 4.6 days, the number of analgesics taken monthly was 45 ± 25.6, 47.5 ± 29.9, the duration of pain was 44.9 ± 24.6, 41.7 ± 22.8 hours respectively. On the 60th day of treatment, the NRS scores in the GON and GON + SON groups was found to be 6.8 ± 2.5, 4.8 ± 2.3, the number of painful days in a month was 4.2 ± 3.3, 2.2 ± 1.5, respectively. The number of monthly analgesic consumption was 4.4 ± 3.8, 0.9 ± 1.2, the duration of pain was 28.4 ± 19.3, 19.4 ± 16.1 hours, respectively. This study showed significant reductions in headache parameters in both groups. However NRS score, analgesic intake, number of painful days and in pain duration significantly better improved in the GON block added to SON block group.

8 January 2026 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
EKEmine Rabia Koç
Emine Rabia Koç
Mehmet Fatih YetkinMehmet Fatih Yetkin
Mehmet Fatih Yetkin
FSFurkan Sarıdaş
Furkan Sarıdaş
OTOmer Faruk Turan
Omer Faruk Turan
SSSerhan Sevim
Serhan Sevim
ASAksel Siva
Aksel Siva
Objective: To evaluate the real-world effectiveness and safety of eculizumab in patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder (NMOSD) and to identify predictors of disability outcomes. Methods: This multinational, retrospective cohort study analyzed data from 46 patients across 26 centers. The outcomes included the annualized relapse rate (ARR), relapse-free status, change in expanded disability status scale (EDSS) scores, and adverse events. To identify predictors of EDSS improvement or worsening, patients were stratified into subgroups (improved vs. stable/worsened) at each follow-up time point and compared based on demographic, clinical, and radiological variables. Results: This retrospective cohort study included 46 patients with AQP4-IgG-positive NMOSD from 26 centers, followed for a mean of 27.3 months. The mean ARR significantly decreased from 1.1 in the 2 years pre-treatment to 0.1 during eculizumab therapy. The relapse-free rate increased from 6.5% pre-treatment to 80.4%. Mean EDSS scores improved from 4.2 at baseline to 3.6 at 24 months. The presence of area postrema syndrome was associated with a favorable prognosis, while the presence of spinal attacks was associated with a poor prognosis at 12 months. Adverse events occurred in 7 patients (18.9%), leading to permanent discontinuation in only two. Conclusion: Eculizumab demonstrated robust real-world effectiveness in reducing relapse rates and stabilizing disability, with an acceptable safety profile. Clinical outcomes may be influenced by attack phenotype, underscoring the importance of early intervention.

26 April 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
ÖKÖmür Karaca
Ömür Karaca
AKAhmet Arman Kibar
Ahmet Arman Kibar
BABurcu Aslantekin
Burcu Aslantekin
NTNermin Tepe
Nermin Tepe
Background: The gyrus rectus is a key brain region with neural connections to the entorhinal cortex and hippocampus, both of which are among the earliest areas affected in Alzheimer’s disease (AD). Investigating volumetric differences and asymmetry in this region may provide insights into disease progression. This study aimed to assess gyrus rectus volume and asymmetry in AD patients using an MRI-based parcellation method. Methods: This cross-sectional volumetric study included 25 cognitively healthy adults and 25 AD patients recruited from the Neurology Clinic of Balıkesir University Hospital. Brain MRI scans were obtained using a 1.5 Tesla MRI scanner. Volumetric measurements were computed using MRIStudio, an atlas-based image analysis program. Group differences in brain volume and asymmetry index were examined, and their correlations with Mini-Mental State Examination (MMSE) scores were evaluated. Results: AD patients exhibited significantly greater rightward volumetric asymmetry of the gyrus rectus volume than healthy controls (p < 0.05). Additionally, a positive correlation was observed between gyrus rectus volume and MMSE scores (p < 0.05). Conclusions: These results suggest that rightward volumetric asymmetry of the gyrus rectus may represent a promising biomarker for tracking the progression of Alzheimer’s disease. Detecting asymmetry in brain structures could improve understanding of AD pathology and aid clinical evaluation.

1 January 2022 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
NTNermin Tepe
Nermin Tepe
HBH. Evren Boran
H. Evren Boran
SGSali̇h Geduk
Sali̇h Geduk
EDErgi̇n Di̇lEköz
Ergi̇n Di̇lEköz
IUİlKay Ulusoy
İlKay Ulusoy
HBHayrunni̇sA Bolay Belen
Hayrunni̇sA Bolay Belen
Background/aim: Discrimination of consecutive sensory stimuli is imperative for proper sensory perception and behavioral response. We aimed to investigate the emergence of paired somatosensory responses in relation to the interstimulus interval (ISI) change. Materials and methods: Paired stimulus with 35 ms, 50 ms, 80 ms, 140 ms, and 500 ms ISI was applied to the median nerve and evoked responses were recorded from the primary somatosensory cortex in rats. Early and late components of both responses were analyzed in different frequency bands. Results: The amplitudes were comparable for the 1st responses (S1), while the amplitude of the 2nd responses (S2), and S2/S1 sensory gating ratio were significantly lower at 35 and 50 ms ISI values. S2/S1 ratio was close to 1 at 500 ms ISI. The duration and latency of the 2nd response was also different at 35 ms ISI. In the 2nd responses, area of early high-frequency oscillations (150-400 Hz) was significantly lower at 35 ms ISI values. Conclusion: The shaping of 2nd somatosensory response is dependent on ISIs. Early high-frequency oscillations changes without accompanying late high-frequency oscillations alterations, may indicate that reduced thalamo-cortical drive to the cortex take a part in determining the 2nd response at short ISI. Further research is required by using neuropsychiatric disorder models where somatosensory perception is impaired.

10 October 2024 in encephalitis
Verified
Journal Article
Open access
PDF file
KEKevser Erdogan
Kevser Erdogan
NTNermin Tepe
Nermin Tepe
GTGülay Turan
Gülay Turan
MÖMusa Öztürk
Musa Öztürk
Immunoglobulin G4 (IgG4)-related disease is an immune-mediated, fibroinflammatory condition that causes multisystemic contrast enhancement and is predominantly observed in elderly male patients. The most prominent features of IgG4-related disease are systemic involvement affecting from two to six systems. In the central nervous system, these contrast enhancements are typically found in the meninges and orbit. This case study describes a 78-year-old female patient with persistent headaches and constant diarrhea who underwent treatment for IgG4-related disease. Despite two months of treatment with non-steroidal and opioid analgesics, the patient remained unresponsive and continued to experience diarrhea for 4 months. Brain magnetic resonance imaging revealed contrast enhancement in the leptomeningeal surfaces, and a biopsy of the gastrointestinal mucosa confirmed the diagnosis of IgG4-related disease, showing widespread plasma cell infiltration and IgG4 expression on plasma cells. The patient was initially treated with 1.0 g/day of pulse therapy for 5 days, followed by a maintenance dose of 1.0 mg/kg oral azathioprine. When azathioprine caused significant pancytopenia, rituximab therapy was initiated. The patient’s headaches resolved completely, and the diarrheal attacks were controlled. This case highlights the importance of considering IgG4-related disease as a potential cause of headache or multiorgan symptoms in elderly patients with new-onset headache unresponsive to conventional analgesics. IgG4-related disease can often be effectively treated with steroids and monoclonal antibodies.

31 December 2022 in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
PDF file
OTOktay Faysal Tertemi̇z
Oktay Faysal Tertemi̇z
NTNermin Tepe
Nermin Tepe
Amaç: Botulinum toksini tip A, kronik migrenin önleyici tedavisi için iyi tolere edilen bir seçenek olarak kabul edilmiştir. Bu çalışmanın amacı, kronik migren tedavisinde botulinum toksin uygulamasının baş ağrısı atak sıklığını, atak şiddetini ve uygulama sayısı artıkça etkinliğinin nasıl olacağını değerlendirmektir. Gereç ve Yöntemler: Medikal tedaviye dirençli kronik migren hastalarından üç ay arayla botulinum toksin A yapılmış hastalardan toplam 29 hastanın verisi toplandı. Demografik verileri, tedavi öncesi aylık atak sıklığı, atak şiddeti, ilacın etkinlik süresini karşılaştırıldı. Bulgular: Botulinum toksini tip A uygulama öncesi ile üçüncü uygulama sonrası karşılaştırıldığında, migren ataklarının aylık sıklığında (21.7 'e karşı 11.4 gün) ve Nümerik derecelendirme skorunda (9.2 'e karşı 5.6) önemli ölçüde iyileşme bulundu (p<0.001). Botulinum toksin etkinliğinin süresi ilk uygulama sonrasında ortalama 3 ay 18 gün, ikinci uygulama sonrasında 3 ay 7 gün, üçüncü uygulama sonrasında 4 ay olarak bulundu. Sonuç: Bu çalışma, Botulinum toksini tip A uygulanan kronik migrenli hastalarda baş ağrısı atak sıklığında ve şiddetinde azalma gösterdi. Uygulama sayısı artıkça hastaların ağrısız gecen sürelerinde de artış bulundu.